Skip to main content
SpringerLink
Log in

Diet and Lifestyle Interventions in Active Surveillance Patients with Favorable-Risk Prostate Cancer

  • Genitourinary Cancer
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Active Surveillance (AS) is a viable, alternative option for patients who are diagnosed with favorable prognostic risk prostate cancer, and who are willing to undergo conservative, expectant management until treatment is warranted due to progression of the disease. Lifestyle interventions in patients who choose AS is an emerging area of research, and several studies are ongoing with results pending. New intervention studies will increase our knowledge of the etiology of prostate cancer and help determine whether dietary factors can influence prostate carcinogenesis after diagnosis in AS patients. The considerable amount of epidemiologic and experimental data relating components of the diet with prostate cancer risk suggest that diet or lifestyle interventions could potentially lengthen the period of active surveillance before treatment management is necessary, and further research is warranted to study the direct effects on secondary clinical outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. American Cancer Society: Cancer Facts and figures 2007. Atlanta: American Cancer Society 2007

  2. Klotz L: Active surveillance for prostate cancer: for whom? J Clin Oncol 2005, 23(32):8165–8169.

    Article  PubMed  Google Scholar 

  3. Bangma CH, Roemeling S, Schroder FH: Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 2007, 25(1):3–9.

    Article  CAS  PubMed  Google Scholar 

  4. Cooperberg MR, Moul JW, Carroll PR: The changing face of prostate cancer. J Clin Oncol 2005, 23(32):8146–8151.

    Article  PubMed  Google Scholar 

  5. Dall’Era MA, Cooperberg MR, Bailey Jr. DE, et al.: Active Surveillance for Early - Stage Prostate Cancer - Rational or Risky? (in submission JCO) 2007.

  6. Johansson JE, Andren O, Andersson SO, et al.: Natural history of early, localized prostate cancer. Jama 2004, 291(22):2713–2719.

    Article  CAS  PubMed  Google Scholar 

  7. D’Amico AV, Whittington R, Malkowicz SB, et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama 1998, 280(11):969–974.

    Article  CAS  PubMed  Google Scholar 

  8. Epstein JI, Walsh PC, Carmichael M, et al.: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. Jama 1994, 271(5):368–374.

    Article  CAS  PubMed  Google Scholar 

  9. Khan MA, Partin AW: Partin tables: past and present. BJU Int 2003, 92(1):7–11.

    Article  CAS  PubMed  Google Scholar 

  10. Kattan MW, Eastham JA, Wheeler TM, et al.: Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003, 170(5): 1792–1797.

    Article  PubMed  Google Scholar 

  11. Cooperberg MR, Pasta DJ, Elkin EP, et al.: The University of California, San Francisco cancer of the prostate risk assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005, 173(6):1938–1942.

    Article  PubMed  Google Scholar 

  12. •• Chan JM, Gann PH, Giovannucci EL: Role of diet in prostate cancer development and progression. J Clin Oncol 2005, 23(32):8152–8160.

    Article  CAS  PubMed  Google Scholar 

This is a review on the role of diet in prostate cancer development and progression and provides a context for the rationale for nutritional interventions in patients who choose AS.

  1. Aydin A, Arsova-Sarafinovska Z, Sayal A, et al.: Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clin Biochem 2006, 39(2):176–179.

    Article  CAS  PubMed  Google Scholar 

  2. Giovannucci E, Rimm EB, Liu Y, et al.: A prospective study of cruciferous vegetables and prostate cancer. Cancer Epidemiol Biomarkers Prev 2003, 12(12):1403–1409.

    CAS  PubMed  Google Scholar 

  3. Xiao D, Singh SV: Phenethyl isothiocyanate inhibits angiogenesis in␣vitro and ex␣vivo. Cancer Res 2007, 67(5):2239–2246.

    Article  CAS  PubMed  Google Scholar 

  4. Hu J, Straub J, Xiao D, et al.: Phenethyl isothiocyanate, a cancer chemopreventive constituent of cruciferous vegetables, inhibits cap-dependent translation by regulating the level and phosphorylation of 4E-BP1. Cancer Res 2007, 67(8):3569–3573.

    Article  CAS  PubMed  Google Scholar 

  5. Basu A, Imrhan V: Tomatoes versus lycopene in oxidative stress and carcinogenesis: conclusions from clinical trials. Eur J Clin Nutr 2007, 61(3):295–303.

    Article  CAS  PubMed  Google Scholar 

  6. Chen L, Stacewicz-Sapuntzakis M, Duncan C, et al.: Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst 2001, 93(24):1872–1879.

    Article  CAS  PubMed  Google Scholar 

  7. Kucuk O, Sarkar FH, Sakr W, et al.: Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2001, 10(8):861–868.

    CAS  PubMed  Google Scholar 

  8. Kucuk O, Sarkar FH, Djuric Z, et al.: Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med (Maywood) 2002, 227(10):881–885.

    CAS  Google Scholar 

  9. Bowen P, Chen L, Stacewicz-Sapuntzakis M, et al.: Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis. Exp Biol Med (Maywood) 2002, 227(10):886–893.

    CAS  Google Scholar 

  10. Stacewicz-Sapuntzakis M, Bowen PE: Role of lycopene and tomato products in prostate health. Biochim Biophys Acta 2005, 1740(2):202–205.

    CAS  PubMed  Google Scholar 

  11. Giovannucci E, Liu Y, Platz EA, et al.: Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007, 121(7):1571–1578.

    Article  CAS  PubMed  Google Scholar 

  12. •• Chan JM, Holick CN, Leitzmann MF, et al.: Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States). Cancer Causes Control 2006, 17(2):199–208.

    Article  PubMed  Google Scholar 

This study examined post-diagnostic diet and risk of prostate cancer progression in a cohort of men with prostate cancer from the Health Professionals Follow-up Study.

  1. Kirsh VA, Mayne ST, Peters U, et al.: A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006, 15(1):92–98.

    Article  CAS  PubMed  Google Scholar 

  2. Peters U, Foster CB, Chatterjee N, et al.: Serum selenium and risk of prostate cancer-a nested case-control study. Am J Clin Nutr 2007, 85(1):209–217.

    CAS  PubMed  Google Scholar 

  3. Li H, Kantoff PW, Giovannucci E, et al.: Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 2005, 65(6):2498–2504.

    Article  CAS  PubMed  Google Scholar 

  4. Weinstein SJ, Wright ME, Pietinen P, et al.: Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study. J Natl Cancer Inst 2005, 97(5):396–399.

    Article  CAS  PubMed  Google Scholar 

  5. Kirsh VA, Hayes RB, Mayne ST, et al.: Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 2006, 98(4):245–254.

    Article  CAS  PubMed  Google Scholar 

  6. Etminan M, FitzGerald JM, Gleave M, et al.: Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysis. Cancer Causes Control 2005, 16(9):1125–1131.

    Article  PubMed  Google Scholar 

  7. • Duffield-Lillico AJ, Reid ME, Turnbull BW, et al.: Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002, 11(7):630–639.

    CAS  PubMed  Google Scholar 

These data, supporting a protective effect of selenium on prostate cancer incidence, led to the initiation of the Watchful Waiting Study, which is testing the effects of selenium on progression of prostate cancer in AS patients.

  1. Sabichi AL, Lee JJ, Taylor RJ, et al.: Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res 2006, 12(7 Pt 1):2178–2184.

    Article  CAS  PubMed  Google Scholar 

  2. Klein EA, Thompson IM, Lippman SM, et al.: SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. J Urol 2001, 166(4):1311–1315.

    Article  CAS  PubMed  Google Scholar 

  3. Marshall JR, Sakr W, Wood D, et al.: Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 2006, 15(8):1479–1484.

    Article  CAS  PubMed  Google Scholar 

  4. Lawson KA, Wright ME, Subar A, et al.: Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst 2007, 99(10):754–764.

    Article  CAS  PubMed  Google Scholar 

  5. Goetzl MA, Vanveldhuizen PJ, Thrasher JB: Effects of soy phytoestrogens on the prostate. Prostate Cancer Prostatic Dis 2007, Feb 20

  6. Holzbeierlein JM, McIntosh J, Thrasher JB: The role of soy phytoestrogens in prostate cancer. Curr Opin Urol 2005, 15(1):17–22.

    Article  PubMed  Google Scholar 

  7. Messina M, Kucuk O, Lampe JW: An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels. J AOAC Int 2006, 89(4):1121–1134.

    CAS  PubMed  Google Scholar 

  8. Yan L, Spitznagel EL: Meta-analysis of soy food and risk of prostate cancer in men. Int J Cancer 2005, 117(4):667–669.

    Article  CAS  PubMed  Google Scholar 

  9. Kurahashi N, Iwasaki M, Sasazuki S, et al.: Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev 2007, 16(3):538–545.

    Article  CAS  PubMed  Google Scholar 

  10. Ozasa K, Nakao M, Watanabe Y, et al.: Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci 2004, 95(1):65–71.

    Article  CAS  PubMed  Google Scholar 

  11. Hedelin M, Balter KA, Chang ET, et al.: Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer. Prostate 2006, 66(14):1512–1520.

    Article  CAS  PubMed  Google Scholar 

  12. Kumar NB, Cantor A, Allen K, et al.: The specific role of isoflavones in reducing prostate cancer risk. Prostate 2004, 59(2):141–147.

    Article  CAS  PubMed  Google Scholar 

  13. deVere White RW, Hackman RM, Soares SE, et al.: Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology 2004, 63(2):259–263.

    Article  PubMed  Google Scholar 

  14. Hedelin M, Chang ET, Wiklund F, et al.: Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Cancer 2007, 120(2):398–405.

    Article  CAS  PubMed  Google Scholar 

  15. Aronson WJ, Glaspy JA, Reddy ST, et al.: Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. Urology 2001, 58(2):283–288.

    Article  CAS  PubMed  Google Scholar 

  16. Rohrmann S, Platz EA, Kavanaugh CJ, et al.: Meat and dairy consumption and subsequent risk of prostate cancer in a US cohort study. Cancer Causes Control 2007, 18(1): 41–50.

    Article  PubMed  Google Scholar 

  17. Rodriguez C, McCullough ML, Mondul AM, et al.: Meat consumption among Black and White men and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2006, 15(2):211–216.

    Article  PubMed  Google Scholar 

  18. Cross AJ, Peters U, Kirsh VA, et al.: A prospective study of meat and meat mutagens and prostate cancer risk. Cancer Res 2005, 65(24):11779–11784.

    Article  CAS  PubMed  Google Scholar 

  19. Tseng M, Breslow RA, Graubard BI, et al.: Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort. Am J Clin Nutr 2005, 81(5):1147–1154.

    CAS  PubMed  Google Scholar 

  20. Giovannucci E, Liu Y, Stampfer MJ, et al.: A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 2006, 15(2):203–210.

    Article  CAS  PubMed  Google Scholar 

  21. Mitrou PN, Albanes D, Weinstein SJ, et al.: A prospective study of dietary calcium, dairy products and prostate cancer risk (Finland). Int J Cancer 2007, 120(11):2466–2473.

    Article  CAS  PubMed  Google Scholar 

  22. Gao X, LaValley MP, Tucker KL: Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. J Natl Cancer Inst 2005, 97(23):1768–1777.

    Article  CAS  PubMed  Google Scholar 

  23. Koh KA, Sesso HD, Paffenbarger RS Jr. et al.: Dairy products, calcium and prostate cancer risk. Br J Cancer 2006, 95(11):1582–1585.

    Article  CAS  PubMed  Google Scholar 

  24. Kristal AR, Cohen JH, Qu P, et al.: Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2002, 11(8):719–725.

    CAS  PubMed  Google Scholar 

  25. Chan JM, Giovannucci E, Andersson SO, et al.: Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 1998, 9(6):559–566.

    Article  CAS  PubMed  Google Scholar 

  26. Li H, Stampfer MJ, Hollis JB, et al.: A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 2007, 4(3):e103.

    Article  PubMed  CAS  Google Scholar 

  27. Kronenwetter C, Weidner G, Pettengill E, et al.: A qualitative analysis of interviews of men with early stage prostate cancer: the Prostate Cancer Lifestyle Trial. Cancer Nurs 2005, 28(2):99–107.

    Article  PubMed  Google Scholar 

  28. Ornish DM, Lee KL, Fair WR, et al.: Dietary trial in prostate cancer: early experience and implications for clinical trial design. Urology 2001, 57(4 Suppl 1):200–201.

    Article  CAS  PubMed  Google Scholar 

  29. Daubenmier JJ, Weidner G, Marlin R, et al.: Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance. Urology 2006, 67(1):125–130.

    Article  PubMed  Google Scholar 

  30. Dunn-Emke SR, Weidner G, Pettengill EB, et al.: Nutrient adequacy of a very low-fat vegan diet. J Am Diet Assoc 2005, 105(9):1442–1446.

    Article  CAS  PubMed  Google Scholar 

  31. •• Ornish D, Weidner G, Fair WR, et al.: Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 2005, 174(3):1065–1069; discussion 1069–1070.

    Article  PubMed  Google Scholar 

This study enrolled AS patients and reported that intensive lifestyle changes may beneficially affect the progression of prostate cancer.

  1. • Stratton MS, Reid ME, Schwartzberg G, et al.: Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: study design and baseline characteristics of the ‹Watchful Waiting’ Study. Anticancer Drugs 2003, 14(8):595–600.

    Article  CAS  PubMed  Google Scholar 

This study provides background information and baseline characteristics of participants in the Watchful Waiting Study, which is currently ongoing and has enrolled patients with AS.

  1. Rock CL: Multivitamin-multimineral supplements: who uses them? Am J Clin Nutr 2007, 85(1):277S–279S.

    CAS  PubMed  Google Scholar 

  2. Wiygul JB, Evans BR, Peterson BL, et al.: Supplement use among men with prostate cancer. Urology 2005, 66(1):161–166.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of CA San Francisco, 1600 Divisadero St., San Francisco, CA, 94143-1695, USA

    Stacey A. Kenfield ScD, Stephanie T. Chang & June M. Chan ScD

Authors
  1. Stacey A. Kenfield ScD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephanie T. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. June M. Chan ScD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to June M. Chan ScD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kenfield, S.A., Chang, S.T. & Chan, J.M. Diet and Lifestyle Interventions in Active Surveillance Patients with Favorable-Risk Prostate Cancer. Curr. Treat. Options in Oncol. 8, 173–196 (2007). https://doi.org/10.1007/s11864-007-0034-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-007-0034-0

Keywords

Search

Navigation